I nterferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy

Abstract

Background Brain atrophy, as assessed by magnetic resonance imaging (MRI), has been correlated with disability in patients with multiple sclerosis (MS). Recent evidence indicates that both white matter (WM) and gray matter (GM) are subject to atrophy in patients with MS. Although neurological deficiencies in MS are primarily due to loss of WM, the clinical significance of GM atrophy has not been fully explored in MS.

Methods We have undertaken a three-year, open-label study, comparing 26 patients who elected to receive intramuscular interferon beta-1a (IFN β-1a) therapy, with 28 patients who elected not to receive therapy. Both groups had quantitative cranial MRI scans at study entry and after three years, and standardized clinical assessments every six months. Brain parenchymal fraction (BPF), GM fraction (GMF), and WM fraction (WMF) percent changes were calculated, and T2- and T1-lesion volumes (LVs) assessed.

Results After three years, mean percent (%) change in BPF favored the IFN β-1a treatment group (IFN β-1a —1.3% versus the control group —2.5%, P=0.009), as did the mean percent change in GMF (+0.2 versus —1.4%, P=0.014), and the mean percent change in T1-LV (—9.3 versus +91.6%, P=0.011). At the end of the study, there was a significant within-patient decrease in BPF for both groups (P=0.02 for the IFN β-1a treatment group, and P<0.001 for the control group), a significant within-patient decrease in WMF for the IFN β-1a treatment group (P=0.01), and a significant decrease in GMF for the control group (P=0.013) when compared with baseline.

Conclusion Over a three-year period, treatment with IFN β-1a significantly slowed the progression of whole-brain and GM atrophy, and of T1-hypointense LV accumulation, when compared with the control group. Multiple Sclerosis 2007; 13: 490-501. http://msj.sagepub.com

Keywords

atrophy brain atrophy gray matter atrophy interferon beta-1a magnetic resonance imaging multiple sclerosis white matter atrophy

Get full access to this article

View all access options for this article.

References

Zivadinov R. , Bakshi R. Role ofl MRI in multiple sclerosis I: inflammation and lesions . Front Biosci 2004; 9: 665-83 .

Zivadinov R. , Bakshi R. Role ofl magnetic resonance imaging in the diagnosis and prognosis ofl multiple sclerosis. In Olek M ed. Multiple sclerosis, etiology, diagnosis, and new treatment strategies. Humana Press , 2005: 55-90.

Miller DH , Barkhof F. , Frank JA , Parker GJ , Thompson AJ Measurement ofl atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance . Brain 2002 ; 125: 1676-95 .

Zivadinov R. , Bakshi R. Brain and spinal cord atrophy in multiple sclerosis. Nova Biomedical Books , 2004.

Zivadinov R. , Bakshi R. Role ofl MRI in multiple sclerosis II: brain and spinal cord atrophy . Front Biosci 2004 ; 9: 647-64 .

Bermel RA , Bakshi R. The measurement and clinical relevance ofl brain atrophy in multiple sclerosis . Lancet Neurol 2006; 5: 158-70 .

Losseff NA , Wang L. , Lai HM , Yoo DS , Gawne-Cain ML , McDonald WI et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study . Brain 1996; 119: 2009-19 .

Rudick RA , Fisher E. , Lee JC , Simon J. , Jacobs L. Use ofl the brain parenchymal flraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group . Neurology 1999; 53: 1698-704 .

Zivadinov R. , Bakshi R. Central nervous system atrophy and clinical status in multiple sclerosis . J Neuroimaging 2004; 14: S27-35 .

10.

Fisher E. , Rudick RA , Simon JH , Cutter G. , Baier M. , Lee JC et al. Eight-year flollow-up study ofl brain atrophy in patients with MS . Neurology 2002; 59: 1412-20 .

11.

Ge Y. , Grossman RI , Udupa JK , Wei L. , Mannon LJ , Polansky M. et al. Brain atrophy in relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis . Radiology 2000; 214: 665-70 .

12.

Bermel RA , Innus MD , Tjoa CW , Bakshi R. Selective caudate atrophy in multiple sclerosis: a 3D MRI parcellation study . Neuroreport 2003; 14: 335-39 .

13.

Chard DT , Griffin CM , Parker GJ , Kapoor R. , Thompson AJ , Miller DH Brain atrophy in clinically early relapsing-remitting multiple sclerosis . Brain 2002; 125: 327-37 .

14.

De Stefano N. , Matthews PM , Filippi M. , Agosta F. , De Luca M. , Bartolozzi ML et al. Evidence ofl early cortical atrophy in MS: relevance to white matter changes and disability . Neurology 2003; 60: 1157-62 .

15.

Fabiano AJ , Sharma J. , Weinstock-Guttman B. , Munschauer FE 3rd, Benedict RH , Zivadinov R. et al. Thalamic involvement in multiple sclerosis: a diflflusion-weighted magnetic resonance imaging study . J Neuroimaging 2003; 13: 307-14 .

16.

Minagar A. Gray matter involvement in multiple sclerosis: a new window into pathogenesis . J Neuroimaging 2003; 13: 291-92 .

17.

Quarantelli M. , Ciarmiello A. , Morra VB , Orefice G. , Larobina M. , Lanzillo R. et al. Brain tissue volume changes in relapsing-remitting multiple sclerosis: correlation with lesion load . Neuroimage 2003; 18: 360-66 .

18.

Amato MP , Bartolozzi ML , Zipoli V. , Portaccio E. , Mortilla M. , Guidi L. et al. Neocortical volume decrease in relapsing-remitting MS patients with mild cognitive impairment . Neurology 2004; 63: 89-93 .

19.

Chen JT , Narayanan S. , Collins DL , Smith SM , Matthews PM , Arnold DL Relating neocortical pathology to disability progression in multiple sclerosis using MRI . Neuroimage 2004; 23: 1168-75 .

20.

Dalton CM , Chard DT , Davies GR , Miszkiel KA , Altmann DR , Fernando K. et al. Early development ofl multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes . Brain 2004; 127: 1101-107 .

21.

Sailer M. , Fischl B. , Salat D. , Tempelmann C. , Schonfeld MA , Busa E. et al. Focal thinning ofl the cerebral cortex in multiple sclerosis . Brain 2003; 126: 1734-44 .

22.

Sanfilipo MP , Benedict RH , Sharma J. , WeinstockGuttman B. , Bakshi R. The relationship between whole brain volume and disability in multiple sclerosis: a comparison ofl normalized gray vs. white matter with misclassification correction . Neuroimage 2005; 26: 1068-77 .

23.

Sastre-Garriga J. , Ingle GT , Chard DT , Cercignani M. , Ramio-Torrenta L. , Miller DH et al. Grey and white matter volume changes in early primary progressive multiple sclerosis: a longitudinal study . Brain 2005; 128: 1454-60 .

24.

Sastre-Garriga J. , Ingle GT , Chard DT , Ramio-Torrenta L. , Miller DH , Thompson AJ Grey and white matter atrophy in early clinical stages ofl primary progressive multiple sclerosis . Neuroimage 2004; 22: 353-59 .

25.

Tiberio M. , Chard DT , Altmann DR , Davies G. , Griffin CM , Rashid W. et al. Gray and white matter volume changes in early RRMS: a 2-year longitudinal study . Neurology 2005; 64: 1001-1007 .

26.

Tjoa CW , Benedict RH , Weinstock-Guttman B. , Fabiano AJ , Bakshi R. MRI T2 hypointensity ofl the dentate nucleus is related to ambulatory impairment in multiple sclerosis . J Neurol Sci 2005; 234: 17-24 .

27.

Valsasina P. , Benedetti B. , Rovaris M. , Sormani MP , Comi G. , Filippi M. Evidence flor progressive gray matter loss in patients with relapsing-remitting MS . Neurology 2005; 65: 1126-28 .

28.

Poser CM , Paty DW , Scheinberg L. , McDonald WI , Davis FA , Ebers GC et al. New diagnostic criteria flor multiple sclerosis: guidelines flor research protocols . Ann Neurol 1983; 13: 227-31 .

29.

Lublin FD , Reingold SC

Defining the clinical course ofl multiple sclerosis: results ofl an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials ofl New Agents in Multiple Sclerosis. Ne

urology 1996; 46: 907-11 .

30.

Zivadinov R. , Rudick RA , De Masi R. , Nasuelli D. , Ukmar M. , Pozzi- Mucelli RS et al. Eflflects ofl IV methylprednisolone on brain atrophy in relapsing-remitting MS . Neurology 2001; 57: 1239-47 .

31.

Hoogervorst EL , Polman CH , Barkhof F. Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone . Mult Scler 2002; 8: 415-19 .

32.

Fox RJ , Fisher E. , Tkach J. , Lee JC , Cohen JA , Rudick RA Brain atrophy and magnetization transfler ratio flollowing methylprednisolone in multiple sclerosis: short-term changes and long-term implications . Mult Scler 2005; 11: 140-45 .

33.

Rao AB , Richert N. , Howard T. , Lewis BK , Bash CN , McFarland HF et al. Methylprednisolone eflflect on brain volume and enhancing lesions in MS beflore and during IFNbeta-1b . Neurology 2002; 59: 688-94 .

34.

Bertolotto A. , Malucchi S. , Sala A. , Orefice G. , Carrieri PB , Capobianco M. et al. Diflflerential eflflects ofl three interfleron betas on neutralising antibodies in patients with multiple sclerosis: a flollow up study in an independent laboratory . J Neurol Neurosurg Psychiatry 2002; 73: 148-53 .

35.

Malucchi S. , Sala A. , Gilli F. , Bottero R. , Di Sapio A , Capobianco M. et al. Neutralizing antibodies reduce the eflficacy ofl betaIFN during treatment ofl multiple sclerosis . Neurology 2004; 62: 2031-37 .

36.

Miller DH , Barkhof F. , Berry I. , Kappos L. , Scotti G. , Thompson AJ Magnetic resonance imaging in monitoring the treatment ofl multiple sclerosis: concerted action guidelines . J Neurol Neurosurg Psychiatry 1991; 54: 683-88 .

37.

Grimaud J. , Lai M. , Thorpe J. , Adeleine P. , Wang L. , Barker GJ et al. Quantification ofl MRI lesion load in multiple sclerosis: a comparison ofl three computer-assisted techniques . Magn Reson Imaging 1996; 14: 495-505 .

38.

Ashburner J. , Friston KJ Voxel-based morphometry- the methods . Neuroimage 2000; 11: 805-21 .

39.

Chard DT , Parker GJ , Griffin CM , Thompson AJ , Miller DH The reproducibility and sensitivity ofl brain tissue volume measurements derived flrom an SPM-based segmentation methodology . J Magn Reson Imaging 2002; 15: 259-67 .

40.

Sanfilipo MP , Benedict RH , Zivadinov R. , Bakshi R. Correction flor intracranial volume in analysis ofl whole brain atrophy in multiple sclerosis: the proportion vs. residual method . Neuroimage 2004; 22: 1732-43 .

41.

Zivadinov R. , Dwyer MG , Watts KL Measurement ofl cerebral grey and white matter atrophy flrom various MRI pulse sequences using diflflerent segmentation algorithms . J Neurol 2004; 251: 335 .

42.

Zivadinov R. , Bagnato F. , Nasuelli D. , Bastianello S. , Bratina A. , Locatelli L. et al. Short-term brain atrophy changes in relapsing-remitting multiple sclerosis . J Neurol Sci 2004; 223: 185-93 .

43.

Conover WJ Practical nonparametric statistics. John Wiley & Sons , 1980.

44.

Siegal S. , Castellan NJ Nonparametric statistics for the behavioral sciences. McGraw-Hill Inc. , 1998.

45.

Filippi M. , Rovaris M. , Inglese M. , Barkhof F. , De Stefano N , Smith S. et al. Interfleron beta-1a flor brain tissue loss in patients at presentation with syndromes suggestive ofl multiple sclerosis: a randomised, double-blind, placebo-controlled trial . Lancet 2004; 364: 1489-96 .

46.

Hardmeier M. , Wagenpfeil S. , Freitag P. , Fisher E. , Rudick RA , Kooijmans M. et al. Rate ofl brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a . Neurology 2005; 64: 236-40 .

47.

Molyneux PD , Kappos L. , Polman C. , Pozzilli C. , Barkhof F. , Filippi M. et al. The eflflect ofl interfleron beta-1b treatment on MRI measures ofl cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interfleron beta-1b in secondary progressive multiple sclerosis . Brain 2000; 123: 2256-63 .

48.

Kidd D. , Barkhof F. , McConnell R. , Algra PR , Allen IV , Revesz T. Cortical lesions in multiple sclerosis . Brain 1999; 122: 17-26 .

49.

Peterson JW , Bo L. , Mork S. , Chang A. , Trapp BD Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions . Ann Neurol 2001; 50: 389-400 .

50.

Kutzelnigg A. , Lucchinetti CF , Stadelmann C. , Bruck W. , Rauschka H. , Bergmann M. et al. Cortical demyelination and diflfluse white matter injury in multiple sclerosis . Brain 2005; 128: 2705-12 .

51.

Trapp BD , Peterson J. , Ransohoff RM , Rudick R. , Mork S. , Bo L. Axonal transection in the lesions ofl multiple sclerosis . N Engl J Med 1998; 338: 278-85 .

52.

Zivadinov R. , Srinivasaraghavan B. , Abdelrahman N. , Hussein S. , Bergsland N. , Dwyer MG Extent ofl gray and white matter atrophy in patients with multiple sclerosis is inversely related to disease duration and disability . Mult Scler 2005; 11 (Suppl. 1): S145 .

53.

Carone DA , Benedict RH , Dwyer MG , Cookfair DL , Srinivasaraghavan B. , Tjoa CW et al. Semi-automatic brain region extraction (SABRE) reveals superior cortical and deep gray matter atrophy in MS . Neuroimage 2006; 29: 505-14 .

54.

Locatelli L. , Zivadinov R. , Grop A. , Zorzon M. Frontal parenchymal atrophy measures in multiple sclerosis . Mult Scler 2004; 10: 562-68 .

55.

Benedict Rhb , Zivadinov R. , Carone DA , Weinstock-Guttman B. , Gaines J. , Maggiore C. et al. Regional lobar atrophy predicts memory impairment in multiple sclerosis. Am J Neuroradiol (AJNR) 2005; 26: 1824-31 .

56.

Jacobs LD , Cookfair DL , Rudick RA , Herndon RM , Richert JR , Salazar AM et al. Intramuscular interfleron beta-1a flor disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Ann Neurol 1996; 39: 285-94 .

57.

Paty DW , Li DK Interfleron beta-1b is eflflective in relapsing-remitting multiple sclerosis. II. MRI analysis results ofl a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group . Neurology 1993; 43: 662-67 .

58.

Prisms (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) study group. Randomised double-blind placebo-controlled study ofl interfleron beta-1a in relapsing/remitting multiple sclerosis . Lancet 1998; 352: 1498-504 .

59.

Clanet M. , Radue EW , Kappos L. , Hartung HP , Hohlfeld R. , Sandberg-Wollheim M. et al. A randomized, double-blind, dose-comparison study ofl weekly interfleron beta-1a in relapsing MS . Neurology 2002; 59: 1507-17 .

60.

Jacobs LD , Beck RW , Simon JH , Kinkel RP , Brownscheidle CM , Murray TJ et al. Intramuscular interfleron beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group . N Engl J Med 2000; 343: 898-904 .

61.

Kappos L. , Clanet M. , Sandberg-Wollheim M. , Radue EW , Hartung HP , Hohlfeld R. et al. Neutralizing antibodies and eflficacy ofl interfleron beta-1a: a 4-year controlled study . Neurology 2005; 65: 40-47 .

62.

Zivadinov R. , Grop A. , Sharma J. , Bratina A. , Tjoa CW , Dwyer M. et al. Reproducibility and accuracy ofl quantitative magnetic resonance imaging techniques ofl whole-brain atrophy measurement in multiple sclerosis . J Neuroimaging 2005 ; 15: 27-36 .